Skip to main content
. Author manuscript; available in PMC: 2015 Dec 1.
Published in final edited form as: Mol Cancer Ther. 2014 Oct 15;13(12):2784–2792. doi: 10.1158/1535-7163.MCT-14-0593

Figure 5. CD30 knockdown reduces brentuximab vedotin efficacy in Kem III but not Karpas 299 cells.

Figure 5

Cells were nucleofected with scrambled (SCR) or CD30 siRNA and two days later, treated with 1 nM brentuximab vedotin for the indicated number of hours. Viability after brentuximab vedotin treatment was determined by MTS assay for (A) Kem III and (B) Karpas 299. Each data point was first normalized to its own untreated control to account for differences in viability unrelated to brentuximab vedotin treatment. *p<0.05 vs SCR control as determined by t-test. Knockdown efficiency was quantified by immunoblotting for CD30 (inset), where numbers represent CD30 to actin ratios normalized to the scrambled siRNA treated sample.